Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
Martin G. Sanda, M.D., Rodney L. Dunn, M.S., Jeff Michalski, M.D., Howard M. Sandler, M.D., Laurel Northouse, R.N., Ph.D., Larry Hembroff, Ph.D., Xihong Lin, Ph.D., Thomas K. Greenfield, Ph.D., Mark S. Litwin, M.D., M.P.H., Christopher S. Saigal, M.D., M.P.H., Arul Mahadevan, M.D., Eric Klein, M.D., Adam Kibel, M.D., Louis L. Pisters, M.D., Deborah Kuban, M.D., Irving Kaplan, M.D., David Wood, M.D., Jay Ciezki, M.D., Nikhil Shah, D.O., and John T. Wei, M.D.
Background We sought to identify determinants of health-relatedquality of life after primary treatment of prostate cancer andto measure the effects of such determinants on satisfactionwith the outcome of treatment in patients and their spousesor partners.
Methods We prospectively measured outcomes reported by 1201patients and 625 spouses or partners at multiple centers beforeand after radical prostatectomy, brachytherapy, or external-beamradiotherapy. We evaluated factors that were associated withchanges in quality of life within study groups and determinedthe effects on satisfaction with the treatment outcome.
Results Adjuvant hormone therapy was associated with worse outcomesacross multiple quality-of-life domains among patients receivingbrachytherapy or radiotherapy. Patients in the brachytherapygroup reported having long-lasting urinary irritation, boweland sexual symptoms, and transient problems with vitality orhormonal function. Adverse effects of prostatectomy on sexualfunction were mitigated by nerve-sparing procedures. After prostatectomy,urinary incontinence was observed, but urinary irritation andobstruction improved, particularly in patients with large prostates.No treatment-related deaths occurred; serious adverse eventswere rare. Treatment-related symptoms were exacerbated by obesity,a large prostate size, a high prostate-specific antigen score,and older age. Black patients reported lower satisfaction withthe degree of overall treatment outcomes. Changes in qualityof life were significantly associated with the degree of outcomesatisfaction among patients and their spouses or partners.
Conclusions Each prostate-cancer treatment was associated witha distinct pattern of change in quality-of-life domains relatedto urinary, sexual, bowel, and hormonal function. These changesinfluenced satisfaction with treatment outcomes among patientsand their spouses or partners.
Source Information
From the Departments of Surgery (M.G.S.) and Radiation Oncology (I.K.), Beth Israel Deaconess Medical Center and Harvard Medical School, and the Department of Biostatistics (X.L.), School of Public Health, Harvard University, Boston; Biostatistics Core (R.L.D.) and the Departments of Radiation Oncology (H.M.S.) and Urology (D.W., N.S., J.T.W.), School of Medicine, and School of Nursing (L.N.), University of Michigan, Ann Arbor; the Departments of Radiation Oncology (J.M.) and Urology (A.K.), Washington University, St. Louis; the Office for Survey Research, Institute for Public Policy and Social Research, Michigan State University, East Lansing (L.H.); Alcohol Research Group, Public Health Institute, Emeryville, CA (T.K.G.); the Departments of Urology (M.S.L., C.S.S.) and Health Services (M.S.L.), UCLA Center for Health Sciences, Los Angeles; the Departments of Radiation Oncology (A.M., J.C.) and Urology (E.K.), Cleveland Clinic Hospitals, Cleveland; and the Departments of Urology (L.L.P.) and Radiation Oncology (D.K.), M.D. Anderson Cancer Center, Houston.
Address reprint requests to Dr. Sanda at the Division of Urology, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Rabb 440, Boston, MA 02215, or at msanda{at}bidmc.harvard.edu.
Shappley, W. V. III, Kenfield, S. A., Kasperzyk, J. L., Qiu, W., Stampfer, M. J., Sanda, M. G., Chan, J. M.
(2009). Prospective Study of Determinants and Outcomes of Deferred Treatment or Watchful Waiting Among Men With Prostate Cancer in a Nationwide Cohort. JCO
27: 4980-4985
[Abstract][Full Text]
Zietman, A.
(2009). Evidence-Based Medicine, Conscience-Based Medicine, and the Management of Low-Risk Prostate Cancer. JCO
27: 4935-4936
[Full Text]
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J. Jr, Yossepowitch, O., Vickers, A. J., Klein, E. A., Wood, D. P., Scardino, P. T.
(2009). Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. JCO
27: 4300-4305
[Abstract][Full Text]
D'Amico, A. V., Moran, B. J., Braccioforte, M. H., Dosoretz, D., Salenius, S., Katin, M., Ross, R., Chen, M.-H.
(2009). Risk of Death From Prostate Cancer After Brachytherapy Alone or With Radiation, Androgen Suppression Therapy, or Both in Men With High-Risk Disease. JCO
27: 3923-3928
[Abstract][Full Text]
Chen, R. C., Clark, J. A., Talcott, J. A.
(2009). Individualizing Quality-of-Life Outcomes Reporting: How Localized Prostate Cancer Treatments Affect Patients With Different Levels of Baseline Urinary, Bowel, and Sexual Function. JCO
27: 3916-3922
[Abstract][Full Text]
Hashine, K., Kusuhara, Y., Miura, N., Shirato, A., Sumiyoshi, Y., Kataoka, M.
(2009). Health-related Quality of Life using SF-8 and EPIC Questionnaires after Treatment with Radical Retropubic Prostatectomy and Permanent Prostate Brachytherapy. Jpn J Clin Oncol
39: 502-508
[Abstract][Full Text]
Alibhai, S. M.H., Duong-Hua, M., Sutradhar, R., Fleshner, N. E., Warde, P., Cheung, A. M., Paszat, L. F.
(2009). Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes. JCO
27: 3452-3458
[Abstract][Full Text]
Gore, J. L., Kwan, L., Lee, S. P., Reiter, R. E., Litwin, M. S.
(2009). Survivorship Beyond Convalescence: 48-Month Quality-of-Life Outcomes After Treatment for Localized Prostate Cancer. JNCI J Natl Cancer Inst
101: 888-892
[Abstract][Full Text]
Goodwin, P. J., Sridhar, S. S.
(2009). Health-Related Quality of Life in Cancer Patients--More Answers but Many Questions Remain. JNCI J Natl Cancer Inst
101: 838-839
[Full Text]
Sanda, M. G., Kaplan, I. D.
(2009). A 64-Year-Old Man With Low-Risk Prostate Cancer: Review of Prostate Cancer Treatment. JAMA
301: 2141-2151
[Abstract][Full Text]
Porta, M. G. D., Malcovati, L.
(2009). Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. haematol
94: 602-606
[Full Text]
Kilbridge, K. L., Fraser, G., Krahn, M., Nelson, E. M., Conaway, M., Bashore, R., Wolf, A., Barry, M. J., Gong, D. A., Nease, R. F. Jr, Connors, A. F.
(2009). Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population. JCO
27: 2015-2021
[Abstract][Full Text]
Simon, M. A., Dong, X., Nonzee, N., Bennett, C. L.
(2009). Heeding Our Words: Complexities of Research Among Low-Literacy Populations. JCO
27: 1938-1940
[Full Text]
Dale, W., Hemmerich, J., Bylow, K., Mohile, S., Mullaney, M., Stadler, W. M.
(2009). Patient Anxiety About Prostate Cancer Independently Predicts Early Initiation of Androgen Deprivation Therapy for Biochemical Cancer Recurrence in Older Men: A Prospective Cohort Study. JCO
27: 1557-1563
[Abstract][Full Text]
King, J. W., Thomas, S., Corsi, F., Gao, L., Dina, R., Gillmore, R., Pigott, K., Kaisary, A., Stauss, H. J., Waxman, J.
(2009). IL15 Can Reverse the Unresponsiveness of Wilms' Tumor Antigen-Specific CTL in Patients with Prostate Cancer. Clin. Cancer Res.
15: 1145-1154
[Abstract][Full Text]
Montie, J. E., Carducci, M. A., Kuban, D. A.
(2009). Perspectives on the Management of Localized Prostate Cancer: Focus on Radiotherapy. Am Soc Clin Oncol Ed Book
2009: 270-274
[Abstract][Full Text]
Lustberg, M., Shapiro, C. L.
(2009). Physical Challenges of Adult Cancer Survivors. Am Soc Clin Oncol Ed Book
2009: 564-569
[Abstract][Full Text]
(2008). Management of Prostate Cancer. NEJM
359: 2605-2609
[Full Text]
Yu, J. S., Roach, M. III, Arap, W., Vordermark, D., Sanda, M. G., Sandler, H. M., Wei, J. T.
(2008). Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. NEJM
359: 200-202
[Full Text]
Bhatia, S., Robison, L. L.
(2008). Cancer Survivorship Research: Opportunities and Future Needs for Expanding the Research Base. Cancer Epidemiol. Biomarkers Prev.
17: 1551-1557
[Full Text]
(2008). Quality of Life Following Primary Therapy for Prostate Cancer. JWatch Oncology and Hematology
2008: 3-3
[Full Text]